|Bid||31.94 x 900|
|Ask||32.08 x 1300|
|Day's range||31.80 - 33.29|
|52-week range||26.81 - 74.77|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jan 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||73.92|
PASADENA, Calif., November 28, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022. The company is hosting a conference call today, November 28, 2022, at 4:30 p.m. ET to discuss the results.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
PASADENA, Calif., November 21, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: